ALX Oncology (NASDAQ:ALXO) Given “Buy” Rating at HC Wainwright

ALX Oncology (NASDAQ:ALXO)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $25.00 target price on the stock.

A number of other research analysts have also recently issued reports on the stock. Stifel Nicolaus restated a “hold” rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Monday. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, ALX Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $17.83.

ALX Oncology Stock Performance

Shares of ALX Oncology stock opened at $2.58 on Tuesday. The firm has a fifty day moving average of $5.98 and a two-hundred day moving average of $11.20. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.21 and a current ratio of 5.21. The stock has a market capitalization of $134.42 million, a price-to-earnings ratio of -0.69 and a beta of 1.06. ALX Oncology has a 52 week low of $2.42 and a 52 week high of $17.83.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.01. As a group, equities research analysts predict that ALX Oncology will post -2.89 EPS for the current year.

Insider Activity

In related news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $7.90, for a total transaction of $158,000.00. Following the sale, the insider now directly owns 593,447 shares in the company, valued at $4,688,231.30. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Peter S. Garcia bought 12,000 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were acquired at an average price of $8.53 per share, with a total value of $102,360.00. Following the transaction, the chief financial officer now owns 122,348 shares in the company, valued at $1,043,628.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $7.90, for a total value of $158,000.00. Following the transaction, the insider now directly owns 593,447 shares of the company’s stock, valued at approximately $4,688,231.30. The disclosure for this sale can be found here. Insiders sold 46,469 shares of company stock worth $363,666 over the last quarter. 33.40% of the stock is currently owned by company insiders.

Institutional Trading of ALX Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in ALX Oncology during the fourth quarter worth $28,000. CANADA LIFE ASSURANCE Co bought a new stake in ALX Oncology during the 1st quarter worth about $27,000. EntryPoint Capital LLC acquired a new position in shares of ALX Oncology during the 1st quarter worth about $32,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of ALX Oncology by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock valued at $107,000 after acquiring an additional 3,825 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after acquiring an additional 5,200 shares during the last quarter. 97.97% of the stock is currently owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.